Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy. Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy

Understanding how intra-tumoral immune populations coordinate to generate anti-tumor responses following therapy can guide precise treatment prioritization. We performed systematic dissection of an established adoptive cellular therapy, donor lymphocyte infusion (DLI) by analyzing 348,905 single-cell transcriptomes from 74 longitudinal bone-marrow samples of 25 patients with relapsed myeloid leukemia; with a subset evaluated by protein-based spatial analysis. In acute myelogenous leukemia (AML) responders, diverse immune cell types within the bone-marrow microenvironment (BME) were predicted to interact with a clonally expanded population of ZNF683+GZMB+ CD8+ cytotoxic T lymphocytes (CTLs) which demonstrated in vitro specificity for autologous leukemia. This population, originating predominantly from the DLI product, expanded concurrently with NK and B cells. AML nonresponder BME revealed a paucity of crosstalk and elevated TIGIT expression in CD8+ CTLs. Our study highlights recipient BME differences as a key determinant of effective anti-leukemia response and opens new opportunities to modulate cell-based leukemia-directed therapy. Overall design: single-cell RNA sequencing and CITE protein sequencing from 9 AML patients and 16 CML patients, with mutliple time points before and after relapse and treatment with donor lymphocyte infusion *************************************************************** Submitter states that missing raw data are being made available for controlled access in dbGaP. ***************************************************************